4.6 Article

Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation

Journal

ONCOGENESIS
Volume 9, Issue 6, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41389-020-00246-2

Keywords

-

Categories

Funding

  1. FEDER-Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020-Operational Programme for Competitiveness and Internationalisation (POCI), Portugal 2020
  2. Portuguese funds through FCT-FundacAo para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e InovacAo [POCI-01-0145-FEDER-007274]
  3. NORTE 2020 grant [NORTE-01-0145-FEDER-000029, NORTE-01-0145-FEDER-000003]
  4. Wilhelm Sander Stiftung [2018.010.1]
  5. Swiss Cancer League [KLS-3841-02-2016]
  6. FCT [SFRH/BD/111885/2015]
  7. [PTDC/MEC-ONC/29503/2017]
  8. Fundação para a Ciência e a Tecnologia [PTDC/MEC-ONC/29503/2017, SFRH/BD/111885/2015] Funding Source: FCT

Ask authors/readers for more resources

Peritoneal dissemination is a particular form of metastasis typically observed in ovarian cancer and the major cause for poor patient's outcome. Identification of the molecular players involved in ovarian cancer dissemination can offer an approach to develop treatment strategies to improve clinical prognosis. Here, we identified mesothelin (MSLN) as a crucial protein in the multistep process of peritoneal dissemination of ovarian cancer. We demonstrated that MSLN is overexpressed in primary and matched peritoneal metastasis of high-grade serous carcinomas (HGSC). Using several genetically engineered ovarian cancer cell lines, resulting in loss or gain of function, we found that MSLN increased cell survival in suspension and invasion of tumor cells through the mesothelial cell layer in vitro. Intraperitoneal xenografts established with MSLN(high)ovarian cancer cell lines showed enhanced tumor burden and spread within the peritoneal cavity. These findings provide strong evidences that MSLN is a key player in ovarian cancer progression by triggering peritoneal dissemination and provide support for further clinical investigation of MSLN as a therapeutic target in HGSC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available